1.the following patients should be carefully administered
(1) patients with myelosuppression; (2) patients with co-infection; (3) patients with heart disease or patients with previous history; (4) patients with liver damage; (5) patients with renal impairment; (6) patients with liver metastases; 7) patients with peptic ulcer or bleeding; (8) patients with varicella; (9) elderly patients; (10) patients who are using other chemotherapy and radiation therapy; (11) patients who have previously used chemotherapy.
(1) White blood cells and platelets should be closely detected. On the day of administration, white blood cells or platelet counts should be checked. If there is severe bone marrow suppression, the drug should be discontinued. After the bone marrow function is restored, continue to be administered.
(2) Patients with diarrhea need to wait until diarrhea is stopped before continuing to administer. Diarrhea may be a sign of gastrointestinal toxicity, and patients with diarrhea may experience rapid, lethal clinical deterioration, so patients with diarrhea should be carefully monitored until the symptoms disappear completely. If diarrhea and / or mucositis occurs, it is recommended to reduce the dose of fluorouracil
(3) The efficacy and non-risk of this product as postoperative adjuvant chemotherapy have not been established.
(4) Sometimes it can cause serious adverse reactions such as myelosuppression, and may even be fatal. Therefore, regular (especially before the drug and before each medication) clinical examination (such as hematology, liver function, kidney function, etc.) should be performed. When abnormalities are found, the dose should be reduced or discontinued and treated appropriately.
(5) Severe enteritis sometimes causes dehydration and may even be fatal. Therefore, it is necessary to strictly detect and find symptoms such as severe abdominal pain and diarrhea, and stop the administration and appropriate treatment.
(6) Pay full attention to the occurrence or deterioration of infectious diseases and bleeding tendency.
(7) When used in combination with tegafur, use this product at least for a period of 7 days or more.
(8) When using drugs in elderly patients, special attention should be paid to adverse reactions and careful administration.
(9) For patients at the age of childbearing, the impact on the gonads should be considered when medication is needed.
3. Precautions during application
(1) Route of administration
This product is an intravenous drip, not subcutaneous, intramuscular injection.
(2) When administering
This product is administered intravenously, may cause vascular pain, thrombophlebitis, it should pay attention to the injection site and injection method.
(3) Preparation method:
This product does not contain preservatives, so care should be taken to avoid bacterial contamination during preparation. Use within 12 hours after preparation. See "Usage and Dosage" for details.
4.other matters needing attention
(1) It has been reported that this product can induce acute leukemia and myelodysplastic syndrome (MDS) in patients with fluorouracil and other anti-malignant drugs.
(2) Patients with fluorouracil isomerase and dihydropyrimidinase (DPD) deficiency, when given fluorouracil, serious adverse reactions such as diarrhea, endocarditis, blood disorders, neuropsychiatric disorders, etc. may occur at the initial stage of administration.